Navigation Links
Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
Date:9/14/2009

SEATTLE, Sept. 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.

"PIPs were introduced by the European Commission to help ensure that medicines that may have benefit in pediatric indications are evaluated in children," said Jack Singer, CTI's Chief Medical Officer. "Anthracyclines are a mainstay in the treatment of childhood leukemias, lymphomas and solid tumors but long-term cardiotoxicity represents a significant issue. We are planning to evaluate safety and efficacy of pixantrone in pediatric cancer patients."

CTI recently received a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 in the U.S. regarding CTI's New Drug Application (NDA) for pixantrone as potential treatment for relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease return
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
3. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
4. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
5. Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
6. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
7. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
8. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
9. Cell Therapeutics, Inc. Announces Exercise of Overallotment
10. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
11. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a ... Drug Administration (FDA) for the use of Medtronic,s ... (including a newly developed catheter) for use with ... intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ... and forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... Experience to the Leader in ... Cellular Bioenergetic Profiling, N. BILLERICA, ... for real-time measurement of cellular,bioenergetics in microplates, announced today that ... company,s Board of,Directors. In this position, Keegan will apply his ...
... Cadus Corporation (OTC,Bulletin Board: KDUS) announced today financial results for ... for the second quarter of 2007 and for the same ... was $218,960, compared,to net income of $75,387 for the same ... quarter of 2007 was $0.02, compared to basic net,income per ...
... a Phase II study of R1507 ... for the Treatment of Sarcoma, ... its partner, Roche has initiated a Phase II,clinical study of R1507 ... created by Genmab under the company,s,agreement with Roche and initiation of ...
Cached Biology Technology:Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors 2Cadus Reports Second Quarter 2007 Results 2Cadus Reports Second Quarter 2007 Results 3Cadus Reports Second Quarter 2007 Results 4Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2
(Date:12/22/2014)... DENVER , Dec. 22, 2014  The ... for the biometrics industry as Acuity Market Intelligence ... biometrics may finally be open. Acuity forecasts that ... mobile devices that incorporate biometrics will drive a ... 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... announced today that they have entered into ... its proprietary photocleavable biotin reagent for the ... The biggest constraint on successful ... is achieving sufficient sensitivity. SomaLogic,s innovative SOMAmer ...
... 29, 2011) The future brightened for organic chemistry when ... attach organic molecules to pristine graphene, making the miracle material ... lab of chemist James Tour, building upon a set of ... method that turned what was a single-atom-thick sheet of carbon ...
... A team of scientists from Worcester Polytechnic Institute ... Life Sciences and Bioengineering Center, have regenerated functional muscle ... clinical therapy to treat people who suffer major muscle ... coax mature human muscle cells into a stem cell-like ...
Cached Biology News:Graphene lights up with new possibilities 2Graphene lights up with new possibilities 3Body rebuilding: Researchers regenerate muscle in mice 2Body rebuilding: Researchers regenerate muscle in mice 3
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... template is designed to allow neomycin/kanamycin selection ... FRT-PGK-gb2-neo-FRT template encodes the neomycin/kanamycin resistance gene ... expression of kanamycin resistance in E.coli ... expression of neomycin resistance in mammalian cells. ...
... This depletion cocktail is tailored ... cells from suspensions of rat ... using the StemSep (or compatible ... selection system. The CD4+ T ...
Biology Products: